Patents Examined by Traviss C. McIntosh, III
  • Patent number: 11667660
    Abstract: The present invention relates to a method for preparing stereodefined phosphorothioate oligonucleotides, especially locked stereodefined phosphorothioate oligonucleotides with a high yield, using pyridinium acidic salts as a coupling activator.
    Type: Grant
    Filed: April 27, 2021
    Date of Patent: June 6, 2023
    Assignee: Roche Innovation Center Copenhagen A/S
    Inventors: Dennis Jul Hansen, Erik Daa Funder
  • Patent number: 11667661
    Abstract: According to the present invention, there are provided a benzimidazole carbamate-sugar compound conjugate compound represented by the following Chemical Formula 1, a preparation method thereof, and a use thereof as an anti-cancer agent: Wherein, R1, R2, R3 and X are as defined in the specification and claims.
    Type: Grant
    Filed: March 8, 2021
    Date of Patent: June 6, 2023
    Assignee: BIOMETRIX TECHNOLOGY INC
    Inventors: Taisun Kim, Keumsoo Song, Junghun Kim
  • Patent number: 11667664
    Abstract: A cyclic dinucleotide compound of Formula (I): wherein X1 is H or F; X2 is H or F; at least one among X1 and X2 is a fluorine atom; Z is OH, OR1, SH or SR1, wherein: R1 is Na or NH4, or R1 is an enzyme-labile group which provides OH or SH in vivo such as pivaloyloxymethyl; B1 and B2 are bases chosen from Adenine, Hypoxanthine or Guanine, and B1 is a different base than B2 and a pharmaceutically acceptable salt thereof. Pharmaceutical compositions including the cyclic dinucleotide, as well as their use in the treatment of a bacterial infection, a viral infection or a cancer are also described.
    Type: Grant
    Filed: July 1, 2021
    Date of Patent: June 6, 2023
    Assignee: KAYLA THERAPEUTICS
    Inventors: Fabienne Vernejoul, Gerard Tiraby, Thierry Lioux
  • Patent number: 11666590
    Abstract: The present invention relates to certain SGLT-2 inhibitors for treating, preventing, protecting against and/or delaying the progression of chronic kidney disease in patients, for example patients with prediabetes, type 1 or type 2 diabetes mellitus.
    Type: Grant
    Filed: November 10, 2020
    Date of Patent: June 6, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Uli Christian Broedl, Odd-Erik Johansen, Eric Williams Mayoux, Nima Soleymanlou, Maximilian von Eynatten, Hans-Juergen Woerle, David Z.I. Cherney, Bruce A. Perkins
  • Patent number: 11660307
    Abstract: Provided are methods for treating 2019-nCoV virus (SARS-CoV-2) infections by administering nucleosides and prodrugs thereof, of Formula I: wherein the 1? position of the nucleoside sugar is substituted.
    Type: Grant
    Filed: January 26, 2021
    Date of Patent: May 30, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Tomas Cihlar, Anuoluwapo Osinusi, Danielle L. Porter
  • Patent number: 11660311
    Abstract: The present invention is directed to compounds of the formula (I), wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: May 30, 2023
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Brian E. Fink, Dharmpal S. Dodd, Yufen Zhao, Lan-Ying Qin, Zheming Ruan, Lalgudi S. Harikrishnan, Muthoni G. Kamau
  • Patent number: 11661436
    Abstract: Methods for preparing 3?-O-amino-2?-deoxyribonucleoside-5?-triphosphates with reduced 3?-hydroxy-2?-deoxyribonucleoside-5?-triphosphate contamination by converting 3?-(N-acetone-oxime)-2?-deoxynucleoside triphosphate to 3?-O-amine-2?-deoxynucleoside triphosphate by treatment with an aryl-oxyamine and compositions produced therefrom.
    Type: Grant
    Filed: March 26, 2021
    Date of Patent: May 30, 2023
    Assignee: DNA SCRIPT SAS
    Inventors: Filip Wojciechowski, Thomas Ybert
  • Patent number: 11655268
    Abstract: The present disclosure relates to a novel nucleoside or nucleotide derivative, a racemate thereof, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for preventing or treating viral infection-associated diseases, containing the same as an active ingredient.
    Type: Grant
    Filed: January 24, 2019
    Date of Patent: May 23, 2023
    Assignee: ST PHARM CO., LTD.
    Inventors: Kyungjin Kim, Meehyein Kim, Uk-Il Kim, Yun Young Go, Hwajung Nam, Hyung Tae Bang, Jin Soo Shin, Jihye Yoon, Yejin Jang
  • Patent number: 11649261
    Abstract: Crystalline forms of the compound of Formula (I), which modulates the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compound and methods for preparing the crystalline forms, are described herein. The use of such crystalline form of Formula (I) and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.
    Type: Grant
    Filed: June 16, 2021
    Date of Patent: May 16, 2023
    Assignee: ARCUS BIOSCIENCES, INC.
    Inventors: Andrew M. K. Pennell, Eric F. Connor, Stephen Edmund Gottschling, Jim Dimetrios Colomvakos, Mohammed Asadullah Khan
  • Patent number: 11643428
    Abstract: The present invention relates to a novel therapeutic drug for a neurodegenerative disease and an application thereof. Provided is a novel compound of formula (I). The compound can effectively facilitate the proliferation of neural stem cells in both in vitro and in vivo experiments and can be used as a treatment approach for facilitating neuroregeneration to fight against cognitive decline associated with aging or a neurodegenerative disease.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: May 9, 2023
    Assignee: Shanghai Pharmaceuticals Holding Co., Ltd.
    Inventors: Gang Pei, Biao Yu, Shichao Huang, Xin Cao, Fuchun Shi, Yue Zhou, Yuqian An, Jing Lu
  • Patent number: 11643431
    Abstract: Disclosed herein is the use of a hyaluronan conjugate for treating pulmonary inflammation, including acute and chronic pulmonary inflammation. Also disclosed herein is the use of a hyaluronan conjugate for treating virus infection. The hyaluronan conjugate is a hyaluronic acid (HA)-nimesulide conjugate.
    Type: Grant
    Filed: June 8, 2021
    Date of Patent: May 9, 2023
    Assignee: AIHOL CORPORATION
    Inventor: Hua-Yang Lin
  • Patent number: 11643660
    Abstract: The present invention provides a novel nucleoside derivative or a salt thereof, a polynucleotide synthesis reagent, a method for producing a polynucleotide, a polynucleotide, and a method for producing a binding nucleic acid molecule. The nucleoside derivative or a salt thereof of the present invention is represented by the following chemical formula (1). In the chemical formula (1), Su is an atomic group having a sugar skeleton at a nucleoside residue or an atomic group having a sugar phosphate skeleton at a nucleotide residue, and may or may not have a protecting group, L1 and L2 are each independently a straight-chain or branched, saturated or unsaturated hydrocarbon group having 2 to 10 carbon atoms, X1 is an imino group (—NR1—), an ether group (—O—), or a thioether group (—S—), and R1 is a hydrogen atom or a straight-chain or branched, saturated or unsaturated hydrocarbon group having 2 to 10 carbon atoms.
    Type: Grant
    Filed: October 12, 2017
    Date of Patent: May 9, 2023
    Assignees: NEC SOLUTION INNOVATORS, LTD., NATIONAL UNIVERSITY CORPORATION GUNMA UNIVERSITY
    Inventors: Hirotaka Minagawa, Katsunori Horii, Jou Akitomi, Naoto Kaneko, Iwao Waga, Masayasu Kuwahara
  • Patent number: 11638716
    Abstract: Disclosed are compounds and compositions for the activation or induction of expression of a pattern recognition receptor (e.g., STING, RIG-I, MDA5), and methods of use thereof.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: May 2, 2023
    Assignee: F-star Therapeutics, Inc.
    Inventors: Radhakrishnan P. Iyer, Anjaneyulu Sheri, Geeta Meher, Sreerupa Challa, Shenghua Zhou
  • Patent number: 11633420
    Abstract: The present invention relates to methods of treating disorders in which DOT1L-mediated protein methylation plays a part, such as cancer, by administering DOT1L inhibitor compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Grant
    Filed: January 4, 2021
    Date of Patent: April 25, 2023
    Assignee: Epizyme, Inc.
    Inventors: Edward J. Olhava, Richard Chesworth, Kevin W. Kuntz, Victoria M. Richon, Roy M. Pollock, Scott Richard Daigle
  • Patent number: 11634450
    Abstract: Provided herein are bifunctional compounds with a moiety (e.g., lenalidomide, thalidomide) that is a binder of an E3 ubiquitin ligase (e.g., Cereblon) and another moiety that is a binder of a target protein DOT1L to induce degradation of DOT1L. Also provided are pharmaceutical compositions comprising the bifunctional compounds, and methods of treating and/or preventing diseases (e.g., proliferative diseases, such as cancers). Provided also are methods of inducing the degradation of DOT1L by administering a bifunctional compound or composition described herein, wherein one component of the bifunctional compound is a binder of an E3 ubiquitin ligase (e.g., lenalidomide, thalidomide) and another component of the compound is a binder of the target protein DOT1L in a subject.
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: April 25, 2023
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Jun Qi, Scott Armstrong, Paul M. Park
  • Patent number: 11629165
    Abstract: Molecule having the structural formula (I): (I) for use as targeting probe of translating ribosomes and ribosome-interacting proteins.
    Type: Grant
    Filed: July 8, 2019
    Date of Patent: April 18, 2023
    Assignee: IMMAGINA BIOTECHNOLOGY S.R.L.
    Inventors: Massimiliano Clamer, Luca Minati
  • Patent number: 11629164
    Abstract: This invention relates to a prodrug of the monophosphate nucleotide of the well-known oncology drug gemcitabine. Specifically, it relates to gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate when present as a single phosphate diastereoisomer and, in particular, it relates to the (S)-phosphate diastereoisomer which offers a remarkable and unexpected increase in solubility relative to the (R)-diastereoisomer. The (S)-phosphate epimer is also preferentially taken up into cyclodextrin solutions over the (R)-diastereoisomer.
    Type: Grant
    Filed: May 4, 2020
    Date of Patent: April 18, 2023
    Assignee: NuCana plc
    Inventors: Hugh Griffith, Christopher McGuigan, Magdalena Slusarczyk, Michaela Serpi, Valentina Ferrari
  • Patent number: 11618765
    Abstract: The disclosure relates to broad spectrum, direct acting antiviral agents. Disclosed is a group of novel nucleoside and nucleotide analogs having a 4-substituted imidazol-2-one heterocycle in place of the pyrimidine base of natural nucleic acid components and their prodrug derivatives (see Formula I).
    Type: Grant
    Filed: May 20, 2021
    Date of Patent: April 4, 2023
    Inventor: Thomas I. Kalman
  • Patent number: 11613552
    Abstract: The present disclosure provides compounds of formulas (1)-(3), and compositions and methods of use thereof. The present disclosure also provides methods of preparing a provided compound and composition, and methods of characterizing a provided compound and composition.
    Type: Grant
    Filed: April 23, 2021
    Date of Patent: March 28, 2023
    Assignee: Alltech, Inc.
    Inventors: Zi-Jian Lan, Ronan Power, Alexandros Yiannikouris, Thirupathi Reddy Yerramreddy
  • Patent number: 11613551
    Abstract: Novel aminoglycosides, represented by Formulae Ia and Ib, as defined in the instant specification, designed to exhibit stop codon mutation readthrough activity, are provided. Also provided are pharmaceutical compositions containing the same, and uses thereof in the treatment of genetic diseases and disorders, such as diseases and disorders associated with stop codon mutations.
    Type: Grant
    Filed: December 17, 2020
    Date of Patent: March 28, 2023
    Assignee: ELOXX PHARMACEUTICALS LTD.
    Inventors: Timor Baasov, Shmuel Tuvia